drug · protein
insulin aspart
pre_registrationupdated 6mo agoby Gan & Lee Pharmaceuticals Co Ltd🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7- druginsulin4 co-mentions · 1 sources
- tagType 2 Diabetes4 co-mentions · 1 sources
- drugFiasp4 co-mentions · 1 sources
- drugType 2 Diabetes2 co-mentions · 1 sources
- companyGan & Lee Pharmaceuticals Co Ltd2 co-mentions · 1 sources
- tagEndocrinology & Metabolism2 co-mentions · 1 sources
- drug(insulin aspart + insulin aspart protamine)2 co-mentions · 1 sources
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and 7 investigational indications.
targets
Insulin receptor
all catalysts(0)
nothing on the calendar yet
Trials studying insulin aspart
- phase1Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
- N/AComparison of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Aspart 30 Injections After Single-Dose Subcutaneous Administration to Healthy Volunteers
- phase1A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump
- phase3A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- phase2Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
- —An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
- phase1A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
- —A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
News(3)
- T-time: British biotech pours $133M into the pot for bispecificsWith backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.biospace · 14d ago
- T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in towT-Therapeutics has pulled in a $133 million series B financing round that will be used to fund the biotech’s lineup of T cell receptor CD3 bispecific drug candidates.fiercebiotech · 16d ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that